Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 3

Sponsor Class

NIH 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 8Sarcoma 6Genitourinary 6Gastrointestinal 6Tumor-Agnostic 4Other solid neoplasm 3Endocrine 3Breast 3Head & Neck 2Dermatologic 2CNS 2NET 1

Conditions

Breast Neoplasms 3Insulin-Like Growth Factor I, Resistance To 1Breast Neoplasms, Male 1

Interventions

Trastuzumab 379Paclitaxel 369Cyclophosphamide 338Docetaxel 314Capecitabine 198Doxorubicin 196Letrozole 184Tamoxifen 154Carboplatin 153Fulvestrant 136Bevacizumab 129Anastrozole 120exemestane 119Lapatinib 117Epirubicin 116Gemcitabine 112Radiotherapy 107palbociclib 94Exercise 87Fluorouracil 83Vinorelbine 82Surveys and Questionnaires 81pertuzumab 77Albumin-Bound Paclitaxel 76Filgrastim 71130-nm albumin-bound paclitaxel 64pembrolizumab 63Everolimus 59Cisplatin 59eribulin 58

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × cixutumumab × Breast × Clear all
NCT00684983 2020-03-24

Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer

National Cancer Institute (NCI)

Phase 2 Completed
64 enrolled 13 charts
Breast

Insulin-Like Growth Factor I, Resistance To, Breast Neoplasms

NCT00699491 2018-06-13

Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
48 enrolled 14 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT00728949 2018-06-06

A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer

Eli Lilly and Company

Phase 2 Completed
93 enrolled 14 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡